Aclaris Therapeutics, Inc. 10-Q

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds ​ None. ​ ​ Item 6. Exhibits ​ ​ Exhibit No. Document ​ ​ ​ 3.1 ​ Amended and Restated Certificate of Incorporation of the Registrant (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-37581), filed with the SEC on October 13, 2015). ​ ​ ​ 3.2 ​ Amended and Restated Bylaws of the Registrant (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-37581), filed with the SEC on June 24, 2020). ​ ​ ​ 10.1*+ ​ ​ Employment Agreement, dated as of June 27, 2022, by and between the Registrant and Gail Cawkwell. ​ ​ ​ 10.2+ ​ ​ Employment Agreement, dated as of August 1, 2022, by and between the Registrant and Douglas Manion (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No. 001-37581), filed with the SEC on August 1, 2022). ​ ​ ​ 31.1* ​ Certification of Principal Executive Officer under Section 302 of the Sarbanes-Oxley Act. ​ ​ ​ 31.2* ​ Certification of Principal Financial Officer under Section 302 of the Sarbanes-Oxley Act. ​ ​ ​ 32.1** ​ Certifications of Principal Executive Officer and Principal Financial Officer under Section 906 of the Sarbanes-Oxley Act. ​ ​ ​ 101.INS ​ XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document) ​ ​ ​ 101.SCH ​ Inline XBRL Taxonomy Extension Schema Document ​ ​ ​ 101.CAL ​ Inline XBRL Taxonomy Extension Calculation Linkbase Document ​ ​ ​ 101.DEF ​ Inline XBRL Taxonomy Extension Definition Linkbase Document ​ ​ ​ 36 Table of Contents 101.LAB ​ Inline XBRL Taxonomy Extension Label Linkbase Document ​ ​ ​ 101.PRE ​ Inline XBRL Taxonomy Extension Presentation Linkbase Document ​ ​ ​ 104 ​ Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) ​ ​ ​ * Filed herewith. ** These certifications are being furnished solely to accompany this quarterly report pursuant to 18 U.S.C. Section 1350, and are not being filed for purposes of Section 18 of the Exchange Act and are not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing. + Indicates management contract or compensatory plan. ​ ​ 37 Table of Contents SIGNATURES ​ Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ​ ​ ​ ​ ​ ACLARIS THERAPEUTICS, INC. ​ ​ ​ Date: August 3, 2022 By: /s/ Neal Walker ​ ​ Neal Walker ​ ​ Chief Executive Officer ​ ​ (On behalf of the Registrant) ​ ​ ​ ​ ​ ​ Date: August 3, 2022 By: /s/ Frank Ruffo ​ ​ Frank Ruffo ​ ​ Chief Financial Officer ​ ​ (Principal Financial Officer) ​ ​ ​ 38